Maneerat Chayanupatkul1, Ronald Omino2, Sahil Mittal3, Jennifer R Kramer4, Peter Richardson4, Aaron P Thrift5, Hashem B El-Serag6, Fasiha Kanwal6. 1. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States. Electronic address: chayanup@bcm.edu. 2. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States. 3. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States; Center of Innovation, Effectiveness and Quality, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States. 4. Center of Innovation, Effectiveness and Quality, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States; Section of Health Services Research, Section of Gastroenterology and Hepatology, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States. 5. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States. 6. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States; Center of Innovation, Effectiveness and Quality, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States; Section of Health Services Research, Section of Gastroenterology and Hepatology, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States.
Abstract
BACKGROUND & AIMS: Cirrhosis related to chronic hepatitis B (CHB) is a major risk factor for hepatocellular carcinoma (HCC). The extent to which HCC occurs in U.S. in the absence of cirrhosis in CHB remains unclear. METHODS: We identified CHB patients who were diagnosed with HCC in the national Veterans Administration (VA) between 2001 and 2013. We defined presence and absence of cirrhosis at the time of HCC diagnosis using explicit histological, radiological, endoscopic, and laboratory criteria. We used multivariable regression analysis to identify demographic and clinical characteristics associated with CHB-related HCC in the absence of cirrhosis. We also examined liver transplant-free survival in CHB-HCC patients with and without cirrhosis. RESULTS: Among 8539 CHB patients, 317 developed HCC of whom 30 (9.5%) did not have any evidence of cirrhosis at the time of HCC diagnosis. Compared to HCC patients with cirrhosis, HCC patients without cirrhosis were more likely to be non-white (African American, OR=6.78; 95% CI 2.05-22.4; Asian, OR 11.6, 95% CI 2.63-50.8), have a family history of HCC (OR 32.9, 95% CI 3.76-288), and hypertension (OR 3.15, 95% CI 1.02-9.75). There was no significant difference in the transplant-free survival between CHB-HCC patients with and without cirrhosis (hazard ratio 0.68, 95% CI 0.43-1.09). CONCLUSIONS: Fewer than 10% of U.S. based CHB-related HCC patients did not have cirrhosis. Race and family history of HCC were the main risk factors for HCC in the absence of cirrhosis in CHB. These factors may help guide the decision to initiate HCC surveillance in CHB patients without cirrhosis. LAY SUMMARY: Patients with chronic hepatitis B who are African American, or Asian, older than 40years of age with family members with liver cancer or high blood pressure are at a higher risk of developing liver cancer in the absence of cirrhosis. These patients should be included in the screening program for liver cancer.
BACKGROUND & AIMS:Cirrhosis related to chronic hepatitis B (CHB) is a major risk factor for hepatocellular carcinoma (HCC). The extent to which HCC occurs in U.S. in the absence of cirrhosis in CHB remains unclear. METHODS: We identified CHB patients who were diagnosed with HCC in the national Veterans Administration (VA) between 2001 and 2013. We defined presence and absence of cirrhosis at the time of HCC diagnosis using explicit histological, radiological, endoscopic, and laboratory criteria. We used multivariable regression analysis to identify demographic and clinical characteristics associated with CHB-related HCC in the absence of cirrhosis. We also examined liver transplant-free survival in CHB-HCCpatients with and without cirrhosis. RESULTS: Among 8539 CHB patients, 317 developed HCC of whom 30 (9.5%) did not have any evidence of cirrhosis at the time of HCC diagnosis. Compared to HCC patients with cirrhosis, HCC patients without cirrhosis were more likely to be non-white (African American, OR=6.78; 95% CI 2.05-22.4; Asian, OR 11.6, 95% CI 2.63-50.8), have a family history of HCC (OR 32.9, 95% CI 3.76-288), and hypertension (OR 3.15, 95% CI 1.02-9.75). There was no significant difference in the transplant-free survival between CHB-HCCpatients with and without cirrhosis (hazard ratio 0.68, 95% CI 0.43-1.09). CONCLUSIONS: Fewer than 10% of U.S. based CHB-related HCC patients did not have cirrhosis. Race and family history of HCC were the main risk factors for HCC in the absence of cirrhosis in CHB. These factors may help guide the decision to initiate HCC surveillance in CHB patients without cirrhosis. LAY SUMMARY:Patients with chronic hepatitis B who are African American, or Asian, older than 40years of age with family members with liver cancer or high blood pressure are at a higher risk of developing liver cancer in the absence of cirrhosis. These patients should be included in the screening program for liver cancer.
Authors: Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong Journal: Hepatology Date: 2018-04 Impact factor: 17.425
Authors: Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi Journal: Saudi J Gastroenterol Date: 2020-10 Impact factor: 2.485
Authors: Jessie Torgersen; Tamar H Taddei; Lesley S Park; Dena M Carbonari; Michael J Kallan; Kisha Mitchell Richards; Xuchen Zhang; Darshana Jhala; Norbert Bräu; Robert Homer; Kathryn D'Addeo; Rajni Mehta; Melissa Skanderson; Farah Kidwai-Khan; Amy C Justice; Vincent Lo Re Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-01 Impact factor: 4.254
Authors: Jessie Torgersen; Michael J Kallan; Dena M Carbonari; Lesley S Park; Rajni L Mehta; Kathryn D'Addeo; Janet P Tate; Joseph K Lim; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; Cynthia L Gibert; Norbert Bräu; Sheldon T Brown; Jason A Roy; Tamar H Taddei; Amy C Justice; Vincent Lo Re Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag Journal: Gastroenterology Date: 2018-08-23 Impact factor: 22.682
Authors: Jully Gogoi-Tiwari; Julia Köhn-Gaone; Corey Giles; Dirk Schmidt-Arras; Francis D Gratte; Caryn L Elsegood; Geoffrey W McCaughan; Grant A Ramm; John K Olynyk; Janina E E Tirnitz-Parker Journal: J Vis Exp Date: 2017-10-21 Impact factor: 1.355
Authors: Jessie Torgersen; Michael J Kallan; Dena M Carbonari; Lesley S Park; Rajni L Mehta; Kathryn D'Addeo; Janet P Tate; Joseph K Lim; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; Norbert Bräu; Sheldon T Brown; Tamar H Taddei; Amy C Justice; Vincent Lo Re Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.731